Tvardi Therapeutics to Participate in Upcoming Investor Events

Rhea-AI Summary

Tvardi Therapeutics (NASDAQ: TVRD) announced that management will participate in three upcoming investor conferences in September 2026. The company will attend the Wells Fargo 21st Annual Healthcare Conference in Boston on September 9 for 1-on-1 meetings, the Cantor Global Healthcare Conference in New York on September 10 for a fireside chat and 1-on-1 meetings at 10:55 AM ET, and the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14 for a company presentation and 1-on-1 meetings at 4:30 PM ET.

The corporate presentation and the H.C. Wainwright webcast will be available on Tvardi's investor website, with a replay accessible for about 90 days.

News Market Reaction – TVRD

-2.20%

-2.20% Session close to close

In the Aug 26 session, TVRD declined 2.20%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will participate in the following upcoming investor events:

Wells Fargo 21^st Annual Healthcare Conference
Format: 1-on-1 Meetings
Date: Wednesday, September 9, 2026
Location: Boston, MA

2026 Cantor Global Healthcare Conference
Format: Fireside Chat and 1-on-1 Meetings
Date: Thursday, September 10, 2026
Time: 10:55 AM ET
Location: New York, NY

H.C. Wainwright 28^th Annual Global Investment Conference
Format: Company Presentation and 1-on-1 Meetings
Date: Monday, September 14, 2026
Time: 4:30 PM ET
Location: New York, NY

The corporate presentation and H.C. Wainwright webcast will be accessible on Tvardi Investors' website. A replay of the webcast will be available for approximately 90 days following the conference.

About Tvardi Therapeutics

Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need. STAT3 is a central mediator across critical signaling pathways that drive immune dysregulation, inflammation and proliferation, survival and, is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. TTI-109 is an oral prodrug of TTI-101, Tvardi's first STAT3 inhibitor, designed to deliver equivalent exposure with improved tolerability. In a completed Phase 1 healthy volunteer study, TTI-109 demonstrated pharmacodynamic STAT3 target engagement, with reductions across disease-relevant cellular and humoral immune cell populations. The Company has selected ulcerative colitis as the initial indication for TTI-109 and plans to initiate a clinical trial pending IND clearance and the availability of additional funding. Tvardi is also conducting a Phase 1b/2 clinical trial of TTI-101 in hepatocellular carcinoma (NCT05440708). To learn more, please visit tvarditherapeutics.com or follow us on LinkedIn and X (Twitter).

Contacts:

For Tvardi:
Tvardi Investor Relations
ir@tvardi.com

PJ Kelleher
LifeSci Advisors
617-430-7579
pkelleher@lifesciadvisors.com

FAQ

When will Tvardi Therapeutics (NASDAQ: TVRD) present at the H.C. Wainwright 28th Annual Global Investment Conference?

Tvardi Therapeutics will present at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026, at 4:30 PM ET. According to Tvardi, this session will include a company presentation and 1-on-1 investor meetings in New York.

How can investors access Tvardi Therapeutics' webcast from the H.C. Wainwright conference in 2026?

Investors can access Tvardi Therapeutics' H.C. Wainwright webcast via the Tvardi Investors' website. According to Tvardi, a replay of the webcast will remain available for approximately 90 days following the conference, allowing extended viewing for shareholders and analysts.

What is Tvardi Therapeutics' schedule at the 2026 Cantor Global Healthcare Conference for TVRD investors?

Tvardi will participate in the 2026 Cantor Global Healthcare Conference on Thursday, September 10, 2026, at 10:55 AM ET. According to Tvardi, the company will host a fireside chat and conduct 1-on-1 investor meetings in New York, NY.

Which investor events will Tvardi Therapeutics (TVRD) attend in September 2026?

Tvardi Therapeutics will attend three events: Wells Fargo’s 21st Annual Healthcare Conference on September 9 in Boston, the Cantor Global Healthcare Conference on September 10 in New York, and the H.C. Wainwright 28th Annual Global Investment Conference on September 14 in New York.

What is the format of Tvardi Therapeutics' participation at the Wells Fargo 21st Annual Healthcare Conference 2026?

At the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026, Tvardi will participate in 1-on-1 investor meetings. According to Tvardi, this event takes place in Boston, MA, and focuses on direct discussions with institutional investors and analysts.

Where can investors find more information or contact Tvardi Therapeutics investor relations about TVRD?

Investors can contact Tvardi via Tvardi Investor Relations at ir@tvardi.com or through LifeSci Advisors representative PJ Kelleher at pkelleher@lifesciadvisors.com. According to Tvardi, additional information is available on tvarditherapeutics.com and the company’s LinkedIn and X (Twitter) accounts.